Investigational immunotherapy nearly doubled overall survival in advanced squamous NSCLC, ASCO Post reports
The ASCO Post published a report on an investigational immunotherapy in advanced squamous non-small cell lung cancer, with a headline citing nearly doubled overall survival.
“Overall Survival Nearly Doubled With Investigational Immunotherapy in Advanced Squamous NSCLC”— The ASCO Post
The ASCO Post has published a report on an investigational immunotherapy for advanced squamous non-small cell lung cancer (NSCLC). Its headline states that overall survival was "nearly doubled".
The text available for this article consists only of the headline. It gives no details on the therapy's name, the trial design, the comparator, the size of the survival benefit or the patient population. LungDaily has therefore not reported any of these.
The therapy is described as investigational, and the source does not mention a regulatory approval or decision. Further details are expected to be in the full ASCO Post article.
